keyword
MENU ▼
Read by QxMD icon Read
search

Lupus therapy

keyword
https://www.readbyqxmd.com/read/28318807/microrna-302d-targets-irf9-to-regulate-the-ifn-induced-gene-expression-in-sle
#1
Siobhán Smith, Thilini Fernando, Pei Wen Wu, Jane Seo, Joan Ní Gabhann, Olga Piskareva, Eoghan McCarthy, Donough Howard, Paul O'Connell, Richard Conway, Phil Gallagher, Eamonn Molloy, Raymond L Stallings, Grainne Kearns, Lindsy Forbess, Mariko Ishimori, Swamy Venuturupalli, Daniel Wallace, Michael Weisman, Caroline A Jefferies
Systemic lupus erythematosus (SLE) is a complex disease targeting multiple organs as a result of overactivation of the type I interferon (IFN) system, a feature currently being targeted by multiple biologic therapies against IFN-α. We have identified an estrogen-regulated microRNA, miR-302d, whose expression is decreased in SLE patient monocytes and identify its target as interferon regulatory factor (IRF)-9, a critical component of the transcriptional complex that regulates expression of interferon-stimulated genes (ISGs)...
March 17, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28317620/lupus-hepatitis-and-autoimmune-hepatitis-lupoid-hepatitis
#2
REVIEW
Avinash Adiga, Kenneth Nugent
Liver dysfunction occurs in approximately 50% of patients with systemic lupus erythematosus (SLE), and patients with SLE and elevated liver enzymes can present a complicated and difficult differential diagnosis. Lupus hepatitis and autoimmune hepatitis are 2 immunologic conditions involving the liver, which can have similar clinical, laboratory and systemic presentations, leading to difficulties in diagnosis. Physicians need to be aware of these 2 hepatic diseases as diagnosis and appropriate therapy need to occur early in the disease course to prevent progression to advanced liver disease...
April 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28301792/systemic-lupus-erythematosus-an-update
#3
Vera Golder, Alberta Hoi
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease predominantly affecting women of childbearing age. New classification criteria for SLE have greater sensitivity and therefore improve the diagnostic certainty for some patients, especially those who may previously have been labelled as having undifferentiated symptoms. Uncontrolled disease activity leads to irreversible end-organ damage, which in turn increases the risk of premature death; early and sustained control of disease activity can usually be achieved by conventional immunosuppressant therapy...
March 20, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28300917/periorbital-discoid-lupus-a-rare-localization-in-a-patient-with-systemic-lupus-erythematosus
#4
Ozgur Cakici, Remzi Karadag, Huseyin Bayramlar, Seyma Ozkanli, Tugba Kevser Uzuncakmak, Ayse Serap Karadag
A 40-year-old female patient with a 5-year history of systemic lupus erythematosus was referred to our policlinic with complaints of erythema, atrophy, and telangiectasia on the upper eyelids for 8 months. No associated mucocutaneous lesion was present. Biopsy taken by our ophthalmology department revealed discoid lupus erythematosus. Topical tacrolimus was augmented to the systemic therapeutic regimen of the patient, which consisted of continuous antimalarial treatment and intermittent corticosteroid drugs...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28300860/annular-elastolytic-giant-cell-granuloma-successfully-treated-with-adalimumab-subsequently-complicated-by-drug-induced-lupus
#5
Adele Haimovic, Hideko Kamino, David E Cohen
We report a 51-year-old female with a 3-year history of recalcitrant annular elastolytic giant cell granuloma (AEGCG) who was effectively treated with the anti-tumor necrosis factor (TNF)-alpha antibody, adalimumab. Her disease was refractory to topical glucocorticoids, intralesional glucocorticoids, narrow-band ultraviolet light (UV)-B phototherapy and cyclosporine. During her treatment with adalimumab she developed a positive anti-nuclear-antibody and double-stranded-DNA antibody and her treatment was terminated...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28300427/annexin-a1-as-a-target-for-managing-murine-pristane-induced-systemic-lupus-erythematosus
#6
Nikolina Mihaylova, Silviya Bradyanova, Petroslav Chipinski, Melinda Herbáth, Stela Chausheva, Dobroslav Kyurkchiev, József Prechl, Andrey I Tchorbanov
Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy...
March 16, 2017: Autoimmunity
https://www.readbyqxmd.com/read/28296238/chinese-sle-treatment-and-research-group-cstar-registry-viii-influence-of-socioeconomic-and-geographical-variables-on-disease-phenotype-and-activity-in-chinese-patients-with-sle
#7
Yongjing Cheng, Mengtao Li, Jiuliang Zhao, Zhizhong Ye, Caifeng Li, Xiaofeng Li, Ping Zhu, Zhengang Wang, Yi Zheng, Xiangpei Li, Miaojia Zhang, Cibo Huang, Xiaofeng Zeng
AIM: The aim of this study was to estimate the influence of socioeconomic and geographical variables on disease phenotype and activity of systemic lupus erythematosus (SLE) in a Chinese population. METHODS: Data on 904 therapy-naïve SLE patients from the Chinese SLE Treatment and Research Group (CSTAR), which is a nation-wide database of SLE patients, were used to evaluate the influence of socioeconomic status (SES) and geographical regions on disease phenotypes...
March 13, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28294088/an-update-on-diet-and-nutritional-factors-in-systemic-lupus-erythematosus-management
#8
Marina Aparicio-Soto, Marina Sánchez-Hidalgo, Catalina Alarcón-de-la-Lastra
Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease characterised by multiple organ involvement and a large number of complications. SLE management remains complicated owing to the biological heterogeneity between patients and the lack of safe and specific targeted therapies. There is evidence that dietary factors can contribute to the geoepidemiology of autoimmune diseases such as SLE. Thus, diet therapy could be a promising approach in SLE owing to both its potential prophylactic effects, without the side effects of classical pharmacology, and its contribution to reducing co-morbidities and improving quality of life in patients with SLE...
March 15, 2017: Nutrition Research Reviews
https://www.readbyqxmd.com/read/28289923/tocilizumab-reverses-cerebral-vasculopathy-in-a-patient-with-homozygous-samhd1-mutation
#9
REVIEW
Michael Henrickson, Heng Wang
An auto-inflammatory syndrome consequent to SAMHD1 mutations involves cerebral vasculopathy characterized by multifocal stenosis and aneurysms within large arteries, moyamoya, chronic ischemia, and early-onset strokes (SAMS). While this condition involves the innate immune system, additional clinical features mimic systemic lupus erythematosus. Mutations in this gene can also cause a subset of the rare genetic condition Aicardi-Goutières syndrome. To date, no established therapy successfully prevents disease progression...
March 13, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28285807/a-brighter-side-to-thalidomide-its-potential-use-in-immunological-disorders
#10
REVIEW
David Millrine, Tadamitsu Kishimoto
Thalidomide and its derivatives are immunomodulatory drugs (IMiDs) known for their sedative, teratogenic, anti-angiogenic, and anti-inflammatory properties. Commonly used in the treatment of cancers such as multiple myeloma and myelodysplastic syndrome (MDS), IMiDs have also been used in the treatment of an inflammatory skin pathology associated with Hansen's disease/leprosy. They have also shown promise in the treatment of autoimmune disorders including systemic lupus erythmatosus (SLE) and inflammatory bowel disease (IBD)...
March 9, 2017: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/28285445/differential-impact-of-systemic-lupus-erythematosus-and-rheumatoid-arthritis-on-health-related-quality-of-life
#11
Benjamin Chaigne, Axel Finckh, Deshire Alpizar-Rodriguez, Delphine Courvoisier, Camillo Ribi, Carlo Chizzolini
PURPOSE: This study examined and compared health-related quality of life (QoL) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). METHODS: We included patients from two multicentric cohorts, the Swiss SLE cohort study (SSCS) and the Swiss Clinical Quality Management Program for RA (SCQM-RA). Patients were matched by age, sex and disease duration using the propensity score. Disease activity was assessed by SELENA-SLEDAI in SLE and by DAS-28 in RA...
March 11, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28284231/support-for-phosphoinositol-3-kinase-and-mtor-inhibitors-as-treatment-for-lupus-using-in-silico-drug-repurposing-analysis
#12
Daniel Toro-Domínguez, Pedro Carmona-Sáez, Marta E Alarcón-Riquelme
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease with few treatment options. Current therapies are not fully effective and show highly variable responses. In this regard, large efforts have focused on developing more effective therapeutic strategies. Drug repurposing based on the comparison of gene expression signatures is an effective technique for the identification of new therapeutic approaches. Here we present a drug-repurposing exploratory analysis using gene expression signatures from SLE patients to discover potential new drug candidates and target genes...
March 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28283734/intestinal-perforation-due-to-hemorrhagic-cytomegalovirus-enteritis-in-a-patient-with-severe-uncontrolled-lupus-nephritis-a-case-and-review-of-the-literature
#13
REVIEW
Keigo Ikeda, Shihoko Nakajima, Kana Tanji, Takuya Hirai, Kaori Uomori, Shinji Morimoto, Shigeki Tomita, Masaki Fukunaga, Naoto Tamura, Iwao Sekigawa
A 31-year-old woman with systemic lupus erythematosus and lupus nephritis was treated with prednisone and immunosuppressants. After her lupus nephritis symptoms worsened, both high-dose steroid and cyclophosphamide pulse therapy were administered. The patient developed an intestinal perforation, and laparoscopic Hartmann's surgery was performed on the sigmoid colon. Serum Cytomegalovirus (CMV) antigen C7HRP was detected, and the patient was diagnosed with CMV colitis and underwent a colon resection. Severe hematochezia continued despite ganciclovir administration, and the patient underwent laparoscopic total colectomy and partial ileostomy...
March 11, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28280970/belimumab-use-clinical-outcomes-and-glucocorticoid-reduction-in-patients-with-systemic-lupus-erythematosus-receiving-belimumab-in-clinical-practice-settings-results-from-the-observe-canada-study
#14
Zahi Touma, Amyn Sayani, Christian A Pineau, Isabelle Fortin, Mark Matsos, George A Ecker, Andrew Chow, Sandra Iczkovitz
To describe the characteristics of patients receiving belimumab, overall patterns of systemic lupus erythematosus (SLE) care, clinical outcomes, and changes in glucocorticoid dose following 6 months of therapy with belimumab, and healthcare resource utilization in belimumab users in Canadian clinical practice settings. Retrospective multicenter medical chart review study of adult patients with SLE who were prescribed belimumab as part of usual care and who received ≥8 infusions or 6 months of treatment...
March 9, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28279836/autologous-hematopoietic-stem-cell-transplantation-in-systemic-lupus-erythematosus-and-antiphospholipid-syndrome-a-systematic-review
#15
REVIEW
Alessia Leone, Massimo Radin, Ahlam M Almarzooqi, Jamal AlSaleh, Dario Roccatello, Savino Sciascia, Munther Khamashta
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results. AIM: To systematically review the literature and analyze the available evidence on HSCT therapy in patients with SLE and antiphospholipid syndrome (APS), with a focus on therapy efficacy and occurrence of adverse events...
March 6, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28275510/aromatase-inhibitors-induced-autoimmune-disorders-in-patients-with-breast-cancer-a-review
#16
REVIEW
George Zarkavelis, Aristomenes Kollas, Eleftherios Kampletsas, Vasilis Vasiliou, Evripides Kaltsonoudis, Alexandros Drosos, Hussein Khaled, Nicholas Pavlidis
Subacute cutaneous lupus erythematosus (SCLE) is characterized by particular cutaneous manifestations such as non-scaring plaques mainly in sunlight exposed parts of the body along with specific serum autoantibodies (i.e. antinuclear antibodies (ANA), Ro/SSa, La/SSb). It is considered either idiopathic or drug induced. The role of chemotherapeutic agents in causing SCLE has been investigated with the taxanes being the most common anticancer agents. However, recent data emerging point toward antiestrogen therapies as a causative factor not only for SCLE but also for a variety of autoimmune disorders...
September 2016: Journal of Advanced Research
https://www.readbyqxmd.com/read/28275260/beyond-tnf-tnf-superfamily-cytokines-as-targets-for-the-treatment-of-rheumatic-diseases
#17
REVIEW
Michael Croft, Richard M Siegel
TNF blockers are highly efficacious at dampening inflammation and reducing symptoms in rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and also in nonrheumatic syndromes such as inflammatory bowel disease. As TNF belongs to a superfamily of 19 structurally related proteins that have both proinflammatory and anti-inflammatory activity, reagents that disrupt the interaction between proinflammatory TNF family cytokines and their receptors, or agonize the anti-inflammatory receptors, are being considered for the treatment of rheumatic diseases...
March 9, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28267664/carotid-free-floating-thrombus-causing-stroke-in-a-young-woman-with-lupus-anticoagulant-a-case-report-and-review-of-the-literature
#18
Abolfazl Afsharfard, Barmak Gholizadeh, Younes Abdolalian, Seyed Masoud Hosseini
INTRODUCTION: In young adults Stroke is a challenging condition and various tests are needed to diagnose and manage its underlying problems. Free floating thrombosis of internal carotid artery (FFT-ICA) is one of the rare problems among carotid artery diseases which can lead to stroke in adults. Owing to limited cases of FFT-ICA there is not a worldwide accepted consensus on management of FFT-ICA, but some recurrences after medical management have been reported in the literature. PRESENTATION OF CASE: A-25-year old woman was referred to hospital with sudden onset aphasia and right sided hemiparesis...
February 20, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28265845/novel-treatments-in-lupus
#19
REVIEW
Vasileios C Kyttaris
PURPOSE OF REVIEW: The treatment of systemic lupus erythematosus (SLE) still depends on non-specific immunosuppression. Herein, we review promising targeted therapies that have the potential to change this therapeutic paradigm. RECENT FINDINGS: Besides the FDA-approved B lymphocyte stimulator (BLyS) inhibitor, belimumab, interferon-α represents a promising treatment target, albeit with modest effectiveness primarily in non-renal SLE. Preclinical and early-phase clinical trials using biologics and small molecules targeting B and T cell activation as well as the cross-talk between these cells also show promise...
March 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28265683/-recurrent-thromboembolisms-despite-full-anticoagulation-in-a-patient-with-antiphospholipid-syndrome
#20
S Wernicke, K Selleng, S B Felix, A Greinacher, F Hammer
We report on a female patient with confirmed secondary antiphospholipid syndrome (APS) due to underlying systemic lupus erythematosus (SLE). Despite a thromboplastin time within the normal range (international normalized ratio, INR) under treatment with a vitamin K antagonist (VKA), a recurrent thrombotic event occurred, this time as pulmonary embolism due to bilateral deep vein thrombosis. Despite an INR value in the therapeutic range, clotting factors II, VII, IX and X were found to be insufficiently decreased suggesting inefficient anticoagulation...
March 6, 2017: Der Internist
keyword
keyword
41338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"